

argenx to Present at Upcoming Investor Conferences

Breda, the Netherlands / Ghent, Belgium - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that management will present at several upcoming investor conferences in November:

- **Stifel 2016 Healthcare Conference.** Chief Scientific Officer Hans de Haard will present on Wednesday, November 16, 2016 at 3:45 p.m. ET in New York City.
- **Jefferies 2016 London Healthcare Conference.** Members of management will be available for 1x1 meetings on Wednesday and Thursday, November 16-17, 2016 in London.
- **Oppenheimer Life Sciences Summit.** Members of management will be available for 1x1 meetings on Tuesday, November 29, 2016 in New York City.
- **Piper Jaffray 28th Annual Healthcare Conference.** Chief Executive Officer Tim Van Hauwermeiren will present on Wednesday, November 30, 2016 at 10:30 a.m. ET in New York City.

Live webcasts of the presentations will be available on the Company's website at www.argenx.com.
Replays of the webcasts will be available for 90 days following the presentation.

About argenx

argenx combines the diversity of the llama immune system with antibody engineering to advance a clinical pipeline to treat patients with cancer and autoimmune diseases. Our platforms allow us to unlock novel and complex targets and develop antibody-based drugs designed for longer duration of effect and greater efficacy. The strength of our team, our deep understanding of the biology, and our committed collaborations with industry leaders contribute to the success of our journey.

For further information, please contact:

Joke Comijn, Corporate Communications Manager
+32 (0)477 77 29 44
+32 (0)9 310 34 19
info@argenx.com

Beth DelGiacco (US IR)
Stern Investor Relations
+1 212 362 1200
beth@sternir.com

Forward-looking Statements

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements argenx makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking statements. argenx undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.